Zacks Investment Research
15 Jul 2026, 14:55 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
The mean analyst price target for Q32 Bio (QTTB) is $33.25, representing a potential upside of 80.1% from its current price of $18.46. — A high consensus price target can attract momentum buyers and increase demand for the stock.
+0.60Analysts are in agreement that Q32 Bio will report earnings that exceed previous estimates. — Positive earnings estimate revisions are typically a strong catalyst for short-term price appreciation.
+0.50Q32 Bio shares have gained 44.8% over the last four weeks. — Strong recent price action confirms positive momentum but may also signal the stock is becoming overbought.
+0.20Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
The stock has gained 44.8% over four weeks and has a mean analyst price target suggesting 80.1% further upside.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
2h ago
